

Certificate of Analysis

Plk3, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-572, 14-572-K, 14-572M

Parent Lot # D12MP022N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant human Plk3 residues 19–301, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 77% by SDS-PAGE and Coomassie blue staining. MW = 36kDa.

Specific Activity (Parent lot# D12MP022N): 1532U/mg, where one unit of Plk3, active activity is defined as 1nmol phosphate incorporated into 2mg/ml casein per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.420mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 20mM β-glycerophosphate, 0.25mM sodium orthovanadate, 10mM NaF, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 1–14ng of this lot of enzyme phosphorylated 2mg/ml casein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as Plk3 with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH 7.0, 1mM EDTA.
2. **Casein:** Use at a final assay concentration of 2mg/ml. Prepare a 20mg/ml stock and add 2.5µl of stock per assay point.
3. **Plk3, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 1mg/ml BSA. Use 1–14ng per assay point.
4. **[γ -³³P]ATP:** 2.5x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **Casein**.
3. Add **2.5µl (1–14ng) Plk3, active**.
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ -³²P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

Plk3 Sequence Information

<u>Protein</u>	human Plk3
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	S31 of the fusion protein is equivalent to S19 of human Plk3
<u>Accession number</u>	GenBank NM_004073

Recombinant Plk3 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMSLGS SGRTYLGKRL LGKGGFARCY EATDTETGSA
61 YAVKVIPQSR VAKPHQREKI LNEIELHRDL QHRHIVRFSH HFEDADNIYI FLELCSRKSL
121 AHIWKARHTL LEPEVRYYL RQILSGLKYLH QRGILHRDLK LGNFFITENM ELKVGDFGLA
181 ARLEPPEQRK KTICGTPNYV APEVLLRQGH GPEADVWSLG CVMYTLCCGS PPFETADLKE
241 TYRCIKQVHY TLPASLSLPA RQLLAAILRA SPRDRPSIDQ ILRHDFFTKG YTPDRLPISS
301 CVTVPDLTPP NPA

```

Recombinant Plk3 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg ggcgatgctc ccttggatcc agcggccgca cctacctcaa aggccgcttg
121 ttgggcaagg ggggcttcgc ccgctgctac gaggccactg acacagagac tggcagcgcc
181 tacgctgtca aagtcattccc gcagagccgc gtcgccaagc cgcattcagcg cgagaagatc
241 ctaaatgaga ttgagctgca ccgagacctg cagcaccgcc acatcgtgcy tttttcgcac
301 cactttgagg acgctgacaa catctacatt ttcttggagc tctgcagccg aaagtccctg
361 gccacatctt ggaaggcccg gcacaccctg ttggagccag aagtgcgcta ctacctgagg
421 cagatccttt ctggcctcaa gtacttgcac cagcgcggca tcttgcaccg ggacctcaag
481 ttgggaaatt ttttcatcac tgagaacatg gaactgaagg tgggggattt tgggctggca
541 gcccggttgg agcctccgga gcagaggaag aagaccatct gtggcaccct caactatgtg
601 gctccagaag tgctgctgag acagggccac ggccctgagg cggatgtatg gtcactgggc
661 tgtgtcatgt acacgctgct ctgcgggagc cctccctttg agacggctga cctgaaggag
721 acgtaccgct gcatcaagca ggttcactac acgctgcctg ccagcctctc actgcctgcc
781 cggcagctcc tggccgcatc ctttcgggcc tcaccccgag accgcccctc tattgaccag
841 atcctgagcc atgacttctt taccaagggc tacaccccg atcgactccc tatcagcagc
901 tgcgtgacag tcccagacct gacaccccc aaccagctt ag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.